Delays in US FDA approvals for respiratory products
FLOVENT 44 approval is pending; any delay could impact Q4 US revenue growth.
high · management_commentary
Glenmark Pharmaceuticals Limited — Q3 FY26
Glenmark delivered a strong Q3 FY26 with consolidated revenue of INR 3,960 crore, up 15.1% YoY, driven by broad-based growth across markets and currency tailwinds.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Currency depreciation impact on reported growth
Analyst questioned the quantum of currency benefit; management could not quantify, indicating potential overstatement of organic growth.
medium · analyst_questionGross margin pressure from product mix
Excluding out-licensing income, gross margin was lower at 65% due to product mix; recovery depends on new approvals.
medium · data_observationWorking capital normalization challenges
Despite progress, working capital days remain a focus; any slippage could impact cash flow targets.
low · management_commentary